Bionano Genomics, Inc. BNGO revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Bionano Genomics, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $28.5M, 100.0% of the filed sum (-7.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$28.5M100.0%-7.4% yoy
Members sum to the consolidated $28.5M for this period.
- Reportable Segment-$33.3M100.0%-67.9% yoy
Members sum to the consolidated -$33.3M for this period.
- Product$26.7Mshare n/a-1.0% yoy
- Consumable Revenue$14Mshare n/a+9.4% yoy
- Software Revenue$6.41Mshare n/a+3.5% yoy
- Instrument Revenue$6.36Mshare n/a-20.9% yoy
- Product And Service Other$1.76Mshare n/a-53.2% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- EMEA$14.1M49.5%-0.9% yoy
- Americas$12.2M42.7%-10.8% yoy
- Asia Pacific$2.22M7.8%-23.3% yoy
Members sum to the consolidated $28.5M for this period.
- Reportable Segment$6.69M100.0%+3.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.